Literature DB >> 21756006

Preoperative C-reactive protein level adjusted for comorbidities and lifestyle factors predicts overall mortality in localized renal cell carcinoma.

Andrew Michigan1, Timothy V Johnson, Viraj A Master.   

Abstract

PURPOSE: C-reactive protein (CRP), an acute phase reactant, is a non-specific marker of inflammation. Elevations in CRP levels are linked with trauma, infection, autoimmune disease, malignancy, and lifestyle factors, such as smoking and obesity. Previously, we noted a significant association between the preoperative CRP level, 1-year relapse-free survival, and 1-year overall relative survival in patients with localized renal cell carcinoma (RCC). This study sought to determine what effect, if any, lifestyle factors have on the prognostic value of preoperative CRP level for overall survival in individuals with localized RCC.
METHODS: 257 patients with localized RCC who underwent nephrectomy were included in the study. Patients were enrolled between November 2006 and February 2010. The impact of tumor characteristics, lifestyle factors, and preoperative CRP level on overall survival was assessed through univariate and multivariate analyses.
RESULTS: During the study, 15.2% of patients died. Univariate analysis found that tumor size (p < 0.001), tumor stage (p < 0.001), Fuhrman nuclear grade (p < 0.001), Charlson Comorbidity Index score (p < 0.001), smoking status (p = 0.038), and preoperative CRP level (p < 0.001) were significantly associated with overall survival. Only the preoperative CRP level (odds ratio 1.035; 95% confidence interval 1.007, 1.064) remained significantly associated with overall survival upon multivariate analysis.
CONCLUSIONS: Prognostic tools serve an important role in cancer management. Thirty percent of patients with localized RCC ultimately develop metastatic disease despite having potentially curative nephrectomy. Previous research has identified the preoperative CRP level as a significant predictor of overall survival in patients with localized RCC. This study demonstrated that the CRP level remained a robust predictive tool when the analysis was controlled for lifestyle factors, including smoking and obesity. Consequently, clinicians should consider taking preoperative CRP levels into account when treating patients with localized RCC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21756006     DOI: 10.1007/bf03256414

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  25 in total

1.  Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study).

Authors:  Stephen J Nicholls; E Murat Tuzcu; Ilke Sipahi; Paul Schoenhagen; Stanley L Hazen; Fady Ntanios; Chuan-Chuan Wun; Steven E Nissen
Journal:  Am J Cardiol       Date:  2006-04-06       Impact factor: 2.778

2.  Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men.

Authors:  L E Rohde; C H Hennekens; P M Ridker
Journal:  Am J Cardiol       Date:  1999-11-01       Impact factor: 2.778

Review 3.  Prognostic markers in renal cell carcinoma.

Authors:  Börje Ljungberg
Journal:  Curr Opin Urol       Date:  2007-09       Impact factor: 2.309

4.  Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma.

Authors:  T V Johnson; A Abbasi; A Owen-Smith; Andrew Young; K Ogan; J Pattaras; P Nieh; F F Marshall; V A Master
Journal:  J Urol       Date:  2009-12-14       Impact factor: 7.450

5.  Lifestyle-only intervention attenuates the inflammatory state associated with obesity: a randomized controlled study in adolescents.

Authors:  Prabhakaran Balagopal; Donald George; Norman Patton; Hossein Yarandi; William L Roberts; Edward Bayne; Samuel Gidding
Journal:  J Pediatr       Date:  2005-03       Impact factor: 4.406

6.  The relationship between patient physiology, the systemic inflammatory response and survival in patients undergoing curative resection of colorectal cancer.

Authors:  C H Richards; E F Leitch; P G Horgan; J H Anderson; R F McKee; D C McMillan
Journal:  Br J Cancer       Date:  2010-09-28       Impact factor: 7.640

7.  A pilot study to examine the effects of smoking cessation on serum markers of inflammation in women at risk for cardiovascular disease.

Authors:  Virginia Reichert; Xiangying Xue; Diane Bartscherer; Daniel Jacobsen; Christine Fardellone; Patricia Folan; Nina Kohn; Arunabh Talwar; Christine N Metz
Journal:  Chest       Date:  2009-02-18       Impact factor: 9.410

8.  C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients.

Authors:  Pierre I Karakiewicz; Georg C Hutterer; Quoc-Dien Trinh; Claudio Jeldres; Paul Perrotte; Andrea Gallina; Jacques Tostain; Jean-Jacques Patard
Journal:  Cancer       Date:  2007-09-15       Impact factor: 6.860

9.  Prognostic significance of morphologic parameters in renal cell carcinoma.

Authors:  S A Fuhrman; L C Lasky; C Limas
Journal:  Am J Surg Pathol       Date:  1982-10       Impact factor: 6.394

10.  The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer.

Authors:  D J McKeown; D J F Brown; A Kelly; A M Wallace; D C McMillan
Journal:  Br J Cancer       Date:  2004-12-13       Impact factor: 7.640

View more
  2 in total

Review 1.  C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review.

Authors:  Shiva Shrotriya; Declan Walsh; Nabila Bennani-Baiti; Shirley Thomas; Cliona Lorton
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

2.  Interleukin-1β mediates metalloproteinase-dependent renal cell carcinoma tumor cell invasion through the activation of CCAAT enhancer binding protein β.

Authors:  Brenda L Petrella; Matthew P Vincenti
Journal:  Cancer Med       Date:  2012-06-07       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.